Ceptaris Therapeutics - Ownership and Business Overview

Life ScienceCompany

Ceptaris Therapeutics Ownership

Who owns Ceptaris Therapeutics?

Ceptaris Therapeutics is owned by Actelion. It was acquired on July 31, 2013.

Ceptaris Therapeutics Business Overview

Where is Ceptaris Therapeutics headquartered?

Ceptaris Therapeutics is headquartered in Malvern, Pennsylvania.

What sector is Ceptaris Therapeutics in?

Ceptaris Therapeutics is a life science company.

When was Ceptaris Therapeutics founded?

Ceptaris Therapeutics was founded in 2002.

Life Science M&A Summary in 2013

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.

Join Mergr to view all 192 acquisitions of life science companies in 2013, including 26 acquisitions by private equity firms, and 166 by strategics.

Ceptaris Therapeutics, Inc.

101 Lindenwood Drive, Suite 400,
Malvern, Pennsylvania 19355
United States,
(610) 975-9290

Ceptaris Therapeutics Inc. is a specialty pharmaceutical company that was established to develop a proprietary gel formulation of mechlorethamine for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of CTCL. If approved, Ceptaris' investigational drug would be the first FDA-approved topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.


 Subscribe to unlock this and 207,390
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.